BMS, bluebird bio bag Abecma FDA approval for multiple myeloma in adults
Abecma FDA approval : Bristol Myers Squibb (BMS) and bluebird bio have secured approval from the US Food and Drug Administration (FDA) for Abecma (idecabtagene ... Read More
BMS gets Opdivo EC approval for second-line treatment of ESCC
Opdivo EC approval : Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for its immunotherapy Opdivo (nivolumab) as a second-line treatment ... Read More
Bristol Myers Squibb wraps up $13.1bn acquisition of MyoKardia
Bristol Myers Squibb has wrapped up its previously announced $13.1 billion acquisition of MyoKardia, a California-based clinical-stage biopharma company. Following the closing of the deal, ... Read More
BMS’ Zeposia succeeds in True North clinical trial in ulcerative colitis
Bristol Myers Squibb (BMS) said that the phase 3 True North clinical trial evaluating Zeposia (ozanimod) in adult patients with moderate to severe ulcerative colitis ... Read More
Bristol Myers Squibb to acquire MyoKardia to gain access to mavacamten
Bristol Myers Squibb (BMS) has agreed to acquire California-based clinical-stage biopharma company MyoKardia for $13.1 billion, to gain access to the latter’s cardiovascular drug candidate ... Read More
FDA approves BMS’ Opdivo, Yervoy combo for malignant pleural mesothelioma
Bristol Myers Squibb (BMS) has secured approval for Opdivo (nivolumab) and Yervoy (ipilimumab) combination from the US Food and Drug Administration (FDA) for the first-line ... Read More
EC approves Reblozyl for transfusion-dependent anemia in adults
Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed erythroid maturation agent Reblozyl (luspatercept) for the ... Read More
Bristol-Myers Squibb wraps up $74bn acquisition of Celgene
Bristol-Myers Squibb has wrapped up its $74 billion acquisition of Celgene having got regulatory approval from all government authorities necessary for closing the merger agreement ... Read More
FTC clears decks for Bristol-Myers Squibb acquisition of Celgene
Bristol-Myers Squibb acquisition of Celgene : US pharma giant Bristol-Myers Squibb said that the US Federal Trade Commission (FTC) has given its clearance for its ... Read More
BMS’ Opdivo flops in CheckMate -331 trial in small cell lung cancer
Bristol-Myers Squibb (BMS) cancer drug Opdivo (nivolumab) failed to meet the primary endpoint of the phase 3 CheckMate -331 trial in small cell lung cancer ... Read More